CA
NZ
UK
AU
IND
US
1. Rating Moves Straight From Overweight to Underweight:The two-notch revision skips the neutral position entirely, signalling a wholesale change of view rather than a marginal adjustment.
1. European Regulatory Consensus Enables a 4Q 2026 Trial Start:Agreement on the pivotal design removes a category of procedural risk before enrolment begins.
1. Open-Market Purchases Totalled Roughly $117,700:Buying executed at prevailing prices carries a different signal than participation in a negotiated financing.
1. FDA Cleared the Label Update Four Months Before the PDUFA Target Date:Early action generally indicates a review without substantive outstanding questions.
1. One Clear Failure and One Clear Approval Framed the Period:Longeveron (NASDAQ: LGVN) missed a Phase 2b primary endpoint while Nuvation Bio (NYSE: NUVB) secured an early FDA label update.
1. A $180 Million Financing Anchored the Largest Structural Transaction:Aethlon Medical (NASDAQ: AEMD) agreed an all-stockMergerwith North Immunology creating NRTX at a $346.5 million pro formaEquityvalue.
1. ELPIS II Missed Its Primary Efficacy Endpoint at Month 12:The trial recorded no significant difference in right ventricular ejection fraction, with a difference of -0.7 percentage points and a p-value of 0.8336.
1. Roth MKM Opens Coverage at Buy With a $6.00 Price Target:The initiation establishes the research house first published position on the stock rather than adjusting an existing view.
1. All-Stock Transaction Creates a Renamed Company Trading Under NRTX:The combinedBusinesswill operate as North Immunology with a pro formaEquityvaluation near $346.5 million.
1. Three-Party MOU Targets Non-Responding Relapsing-Remitting MS:The agreement brings together Tiziana (NASDAQ: TLSA), KAIMRC and the Foundation for Neurologic Diseases around a defined patient gap.
Please wait processing your request...